SUBSCRIBE
SUBSCRIBE
News   Business

SciGen Ltd Signs US$145 Million Hepatitis B Distribution Deal

October 19, 2005 | 
1 min read
Singapore-based generics company SciGen (ASX:SIE) has signed a Chinese distribution agreement worth at least US$145 million (AUD$191.6 million) with Hefei Life Science Park Investment & Development (HID) for its hepatitis B product, Sci-B-Vac.
Alliances
MORE ON THIS TOPIC
Fantasy background for poster for tourism company. Illustration of stormy sea waves with ancient sailboat Spanish galleon and lighthouse at night. Modern print. Vector cartoon image.
Obesity
Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug
June 2, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Abstract handshake
Mergers & acquisitions
Sanofi Inks $9.5B Blueprint Buyout to Expand Rare Disease Portfolio
June 2, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug
June 2, 2025
 · 
217 min read
 · 
BioSpace Editorial Staff
Illustration showing line of people leaving, standing on top of hand pointing their way out
Layoffs
Stealth Cuts 30% of Workforce Following FDA Rejection, Still Eyes Barth Approval
May 30, 2025
 · 
2 min read
 · 
Angela Gabriel